Logo
x

Search category

Subscribe Now

All Posts by Date

PharmaShots Interview: Daiichi Sankyo's Ken Keller Shares Insights on NICE Recommendation for Enhertu in HER2 Positive Breast Cancer

PharmaShots Interview: Daiichi Sankyo's Ken Keller Shares Insights on NICE Recommendation for Enhertu in HER2 Positive Breast Canc...

  • June 2, 2021
Scynexis' Brexafemme (ibrexafungerp tablets) Receives the US FDA's Approval as the First Oral Non-Azole Treatment for Vaginal Yeast Infections

Scynexis' Brexafemme (ibrexafungerp tablets) Receives the US FDA's Approval as the First Oral Non-Azole Treatment for Vaginal Yeas...

  • June 2, 2021
Novartis' Cosentyx (secukinumab) Receives the US FDA's Approval for the Treatment of Moderate to Severe Plaque Psoriasis

Novartis' Cosentyx (secukinumab) Receives the US FDA's Approval for the Treatment of Moderate to Severe Plaque Psoriasis

  • June 2, 2021
Janssen's Teclistamab Receives the US FDA's Breakthrough Therapy Designation for Relapsed or Refractory Multiple Myeloma

Janssen's Teclistamab Receives the US FDA's Breakthrough Therapy Designation for Relapsed or Refractory Multiple Myeloma

  • June 2, 2021
Alnylam Reports Completion of Patient Enrollment in P-III APOLLO-B Study for Patisiran to Treat Transthyretin-Mediated (ATTR) Amyloidosis with Cardiomyopathy

Alnylam Reports Completion of Patient Enrollment in P-III APOLLO-B Study for Patisiran to Treat Transthyretin-Mediated (ATTR) Amyl...

  • June 2, 2021
AstraZeneca Presents Results of Anifrolumab in New Post-Hoc Analysis of P-III TULIP Study for Systemic Lupus Erythematosus at EULAR 2021

AstraZeneca Presents Results of Anifrolumab in New Post-Hoc Analysis of P-III TULIP Study for Systemic Lupus Erythematosus at EULA...

  • June 2, 2021
Image

Stay Connected

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2023 PharmaShots - All Rights Reserved.